SOURCE-LINKED STUDY SUMMARY
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Abstract summarizedQuality not appraised
- What was studied
- A randomized, double-blind, placebo-controlled phase two substudy tested once-weekly retatrutide for reducing liver fat.
- Who / model studied
- Participants had metabolic dysfunction-associated steatotic liver disease and at least ten percent liver fat.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Retatrutide produced dose-related liver-fat reductions versus placebo, and more participants reached normal liver-fat levels at higher doses.
- Limitations & context
- This was a substudy of ninety-eight selected participants rather than a standalone broad liver-disease trial.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1038/s41591-024-03018-2